Update
$Kintara Therapeutics(KTRA.US$ Tuhura Biosciences and Kintara Therapeutics Announce Positive Results From Phase 1B Trial of Ifx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (Mcc) and Cutaneous Squamous Cell Carcinoma (Cscc)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
